OBI is a Taiwan-based biopharma company founded in 2002 with the headquarter in Taipei and subsidiaries in the United States, China, Hong Kong and Australia. Our mission is to improve health and the quality of life of patients through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancers by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets.

Globo H antigen is highly expressed in multiple cancers including breast, pancreatic, esophageal, gastric, lung, colon and ovarian cancers. Similarly, SSEA-4 antigen has been observed to have high expression in renal, breast, pancreatic, ovarian, brain, and lung cancers. The AKR1C3 enzyme is highly expressed in multiple cancers including liver, kidney, bladder, gastric, castration-resistant prostate cancers and T-ALL.

OBI Pharma has a First-in-Class anti-Globo Series Immuno-Oncology (I-O) pipeline, which includes both active (vaccine) and passive (monoclonal antibody & antibody drug conjugate) therapeutics targeting Globo H (clinical) and SSEA-4 (pre-clinical). OBI also has, currently under clinical development, a First-in-Class small molecule prodrug that targets cancers with overexpression of the Aldo Keto Reductase 1C3 enzyme (AKR1C3).